Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-KK-LC-1 TCR-expressing T cells

A preparation of autologous T lymphocytes that have been genetically engineered to express a T-cell receptor (TCR) specific for the tumor-associated antigen (TAA) Kita-Kyushu lung cancer antigen-1 (KK-LC-1), with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-KK-LC-1 TCR-expressing T cells specifically target and bind to KK-LC-1-expressing tumor cells. This leads to T-cell activation and T-cell mediated lysis of KK-LC-1-expressing tumor cells. KK-LC-1, a cancer germline (CG) antigen, is expressed in a variety of epithelial cancers and has restricted expression in normal tissues.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Autologous Anti-KK-LC-1 TCR-expressing T-cells
KK-LC-1 TCR T cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search